Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 6/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | ERN1 | O75460 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5150668 | 0.88 | ALDH5A1 (0.37) | CYP2A6ALDH5A1ABATPTGS2ESR1 | |
| SCHEMBL5150548 | 0.82 | ESR1 (0.42) | PTGS2ESR1ESR2PELI1HSD17B10 | |
| SCHEMBL5150540 | 0.82 | ESR1 (0.42) | PTGS2ESR1ESR2PELI1HSD17B10 | |
| SCHEMBL5154341 | 0.82 | ESR1 (0.42) | PTGS2ESR1ESR2PELI1HSD17B10 | |
| SCHEMBL5153353 | 0.81 | ALDH1A1 (0.42) | CYP2A6PTGS2ERN1 | |
| SCHEMBL12565812 | 0.78 | ESR1 (0.41) | PTGS2ESR1ESR2PELI1HSD17B10 | |
| SCHEMBL3371199 | 0.76 | CYP2A6 (0.47) | CYP2A6PTGS2ERN1 | |
| SCHEMBL25293128 | 0.75 | PTGS1 (0.50) | CYP2A6ALDH5A1ABATPTGS1HSD17B10 | |
| SCHEMBL29693531 | 0.75 | PTGS1 (0.50) | CYP2A6ALDH5A1ABATPTGS1HSD17B10 | |
| SCHEMBL5153855 | 0.74 | ESR1 (0.43) | PTGS2ESR1ESR2PELI1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100344610-C | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH CORP (US) | 2007-10-24 | — | — | CN | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1633699-B1 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1633699-B1 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157491-B2 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-01-02 | — | — | US | disclosed |
| CN-1791570-A | Aryl-formaldoxime derivatives and their use as estrogenic agents | WYETH CORP (US) | 2006-06-21 | — | — | CN | disclosed |
| EP-1633699-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-13 | — | — | US | disclosed |
| WO-2004103941-A2 | ARYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009907-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRA | CYP2A6 49/4885ALDH5A1 607/4885ABAT 3219/4885 |
| US-20070043077-A1 | Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, GPER1 | CYP2A6 46/4885ALDH5A1 675/4885ABAT 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.